Intervention not reported
Severe local reaction8 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to lower severe local reaction8 (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐severe local reaction11 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to lower non‐severe local reaction11 (moderate certainty).
1 finding from 1 review
Intervention not reported
Fever15 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
It is very uncertain whether the intervention changes fever15 (very low certainty).
1 finding from 1 review
Intervention not reported
2c. Adequate immune response (seroprotection) against pertussis (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
2d. Adequate immune response (seroprotection) against Haemophilus influenzae type b disease (surrogate outcome) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to higher 2d. Adequate immune response (seroprotection) against Haemophilus… (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
4a. Procedural crying (during and immediately after the vaccination procedure) (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
4b. Persistent inconsolable crying4 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
It is very uncertain whether the intervention changes 4b. Persistent inconsolable crying4 (very low certainty).
1 finding from 1 review
Intervention not reported
Severe local reaction8 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to lower severe local reaction8 (moderate certainty).
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
azasetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review